Cet anticorps anti-CEACAM5 (Tusamitamab Biosimilar) est un anticorps Humanized Monoclonal détectant CEACAM5 (Tusamitamab Biosimilar) dans FACS et in vivo. Adapté pour Humain.
N° du produit ABIN7795147
Aperçu rapide pour Recombinant CEACAM5 (Tusamitamab Biosimilar) anticorps (ABIN7795147)
Antigène
CEACAM5 (Tusamitamab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp CEACAM5 (Tusamitamab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Expression System
Mammalian cells
Fonction
Tusamitamab Biosimilar, Human CEACAM5 Monoclonal Antibody
Attributs du produit
What is tusamitamab biosimilar research grade? Tusamitamab is a humanized IgG1-kappa monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) which is overexpressed in tumors including non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and is an attractive target for therapies based on CAR-T cell or/and ADCs. Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC) combining a humanized monoclonal antibody and a potent cytotoxic maytansinoid derivative (DM4) inhibiting microtubule assembly. Tusamitamab biosimilar uses the same protein sequences as the therapeutic antibody tusamitamab.